Company / R&D Expense
Celldex Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$245.1M
FY2025
5-year range
$53.3M / $245.1M
FY2021-FY2025
Trend
+49.8%
vs FY2024
Sector context
#30 of 110
Health Care
What the data says
At $245M, Celldex Therapeutics, Inc.'s r&d expense ranks #30 of 110 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $43M in FY2020 to $245M in FY2025.
Based on SEC 10-K filings.
$245M in FY2025 with a 5-year CAGR of +41.9%.
Improved from $118M to $245M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +43.9%
- 5-Year CAGR
- +41.9%
- 10-Year CAGR
- -
Sector benchmark
#30 of 110 in Health CareTop 27% of 110This company $245.1M Sector average $298.2M
▼
-17.8% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +41.9%, indicating consistent growth.
- In FY2025, r&d expense increased 49.8% year-over-year.
- Ranks #30 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $245.1M | +49.8% |
| FY2024 | $163.6M | +38.6% |
| FY2023 | $118.0M | +43.5% |
| FY2022 | $82.3M | +54.3% |
| FY2021 | $53.3M | +25.3% |
| FY2020 | $42.5M | -0.3% |
| FY2019 | $42.7M | -58.5% |
| FY2018 | $102.7M | +6.8% |
| FY2017 | $96.2M | -6.4% |
| FY2016 | $102.7M | +2.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026